Search / Trial NCT06234826

Skeletal Muscle Wasting in ICU Patients

Launched by FRANK VANDENABEELE · Jan 30, 2024

Trial Information

Current as of December 30, 2024

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how muscle wasting happens in critically ill patients who are in the intensive care unit (ICU). When patients are very sick, their bodies often break down muscle faster than they can build it back up, leading to significant muscle loss. The researchers want to measure how quickly muscle protein is made during a week in these patients and understand the changes at a microscopic level that lead to muscle wasting. They also plan to see if muscle size improves three months after the patients leave the ICU.

To participate in this study, you need to be an adult over 18 years old who is currently in the ICU and expected to stay for more than seven days. You should have a feeding tube in place and an arterial line for monitoring. However, if you have certain conditions like chronic kidney or liver failure, or are using specific medications, you may not be eligible. If you join the study, you can expect to give some information about your health, and you may take part in tests that help researchers understand muscle recovery during your stay in the ICU and beyond.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • age \>18y
  • admitted to ICU
  • enteral nutrition line in situ
  • arterial line (any location) in situ
  • expected stay ICU \>7d
  • Exclusion Criteria:
  • spinal cord injury
  • chronic use of corticosteroids before hospital admission
  • Contraindication to enteral infusion (e.g. due to GI-tract perforation)
  • Kidney or liver failure
  • therapeutic anti coagulation

Trial Officials

Frank Vandenabeele, Prof.

Principal Investigator

Hasselt University

About Frank Vandenabeele

Frank Vandenabeele is a distinguished clinical trial sponsor specializing in innovative research and development in the healthcare sector. With a commitment to advancing medical science, the organization focuses on designing and executing clinical trials that adhere to the highest ethical and regulatory standards. Leveraging a robust network of industry partnerships and a team of experienced professionals, Frank Vandenabeele aims to facilitate the discovery and delivery of novel therapies that improve patient outcomes. Their dedication to transparency and collaboration underscores a mission to contribute significantly to the advancement of medical knowledge and treatment options.

Locations

Hasselt, Limburg, Belgium

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0